Market closed
Bristol-Myers Squibb/$BMY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Ticker
$BMY
Sector
NON_CLASSIFIED
Trading on
NYSE
Industry
Biotechnology & Drugs
Headquarters
Princeton, United States
Employees
34,100
Website
BMY Metrics
BasicAdvanced
$83B
-
-$3.10
0.43
$2.31
5.84%
Price and volume
Market cap
$83B
Beta
0.43
52-week high
$66.46
52-week low
$39.91
Average daily volume
340M
Dividend rate
$2.31
Financial strength
Current ratio
1.11
Quick ratio
0.995
Long term debt to equity
300.103
Total debt to equity
337.641
Interest coverage (TTM)
15.57%
Management effectiveness
Return on assets (TTM)
-6.35%
Return on equity (TTM)
-25.45%
Return on investment (TTM)
-8.27%
Valuation
Price to revenue (TTM)
1.829
Price to book
5.051
Price to free cash flow (TTM)
10.749
Five year average dividend yield
3.16%
Dividend yield (TTM)
5.62%
Forward dividend yield
5.84%
Growth
Revenue change (TTM)
-0.68%
Earnings per share change (TTM)
-190.34%
3-year revenue growth (CAGR)
1.91%
3-year dividend per share growth (CAGR)
8.20%
What the Analysts think about BMY
Analyst Ratings
Majority rating from 27 analysts.
BMY Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12B
3.38%
Net income
-$12B
-775.99%
Profit margin
-100.38%
-753.94%
BMY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.75
$2.00
$1.70
-$4.40
-
Expected
$1.98
$1.76
$1.53
-$4.44
$1.70
Surprise
11.43%
13.64%
11.13%
0.80%
-
BMY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closed
Upcoming events
May1
Bristol-Myers Squibb
Dividend·Payment
$0.62
Per share
FAQs
What’s the current market cap for Bristol-Myers Squibb stock?
Bristol-Myers Squibb (BMY) has a market cap of $83B as of April 24, 2025.
What is the P/E ratio for Bristol-Myers Squibb stock?
The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 0 as of April 24, 2025.
Does Bristol-Myers Squibb stock pay dividends?
Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of April 24, 2025, the dividend rate is $2.31 and the yield is 5.84%. Bristol-Myers Squibb has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Bristol-Myers Squibb dividend payment date?
The next Bristol-Myers Squibb (BMY) dividend payment is scheduled for May 01, 2025.
What is the beta indicator for Bristol-Myers Squibb?
Bristol-Myers Squibb (BMY) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.